Migraine - Opportunities will exist in the wake of generic attack

"IntroductionWith the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.ScopeThis report focuses on acute and prophylactic drugs used to treat migraine, with indication- and country-specific sales and volume forecasts to 2016 Assessment of current and future opportunities and threats in the migraine market across the 7MMs and in individual regions Analysis and quantification of future market events expected to impact anti-migraine drug revenues over the next decade Case study analysis of successful lifecycle management strategies and scenario forecasts provide further market insight and key recommendationsHighlightsGSK has executed a number of well-timed lifecycle management strategies that have ensured Imitrex's market leadership. However, Imitrex's impending patent expiry will result in generic sumatriptan flooding the US market in late 2008, and crucial delays to Trexima's launch will signal the end of GSK's dominance of the migraine market. There remains substantial opportunity in the migraine prophylaxis market. In spite of US Topamax patent expiry in 2008, the large number of untreated patients and poor tolerability profiles of existing treatments means the prophylactic market will remain highly attractive over the forecast period. Menstrual migraine (MM) represents an unknown, yet potentially rewarding market opportunity. Endo and Vernalis's Frova (frovatriptan) awaits the FDA's decision on its application for the short-term prevention of MM. This outcome will be crucial to the drug's future and will also influence other triptan manufacturers' decision to pursue MM.Reasons to PurchaseQuantify the future size of the migraine market, in terms of prescription volume and value, in each of the seven major markets Assess the impact of future events such as patent expiries, indication expansions, and new product launches on the sales of key marketed brands Identify key lifecycle management strategies and market opportunities that can ensure growth in the competitive anti-migraine pharmaceutical arena"

26-Sep-07 Format: PDF & SlidePack & DataPack Page: 187
Table of Contents
Price: $15,200.00 / GBP7,600.00